Ivabradine Alter (Ivabradine Hydrochloride)

• Ivabradine acts on the cardiac If current to control heart rate in several cardiovascular conditions.
• Chronic stable angina: reduces frequency of angina attacks by lowering heart rate.
• Heart failure (NYHA class II‑III): improves symptoms and may reduce hospitalizations by decreasing cardiac workload.
• Elevated resting heart rate: provides rate control without affecting myocardial contractility.

• Ivabradine selectively inhibits the funny (If) current in the sino‑atrial node by binding to the HCN channel pore. This reduces the spontaneous depolarisation rate of pacemaker cells, leading to a dose‑dependent decrease in heart rate while preserving myocardial contractility and blood pressure. The effect is independent of the autonomic nervous system, allowing heart‑rate lowering without β‑adrenergic blockade.

Ivabradine may be associated with several adverse reactions, which are classified by frequency.

Common Side Effects

• Visual disturbances (phosphenes): transient luminous phenomena.
• Bradycardia: symptomatic slow heart rate.
• Headache: mild to moderate intensity.
• Dizziness: especially upon standing.

Serious or Rare Side Effects

• Symptomatic severe bradycardia requiring medical intervention.
• Atrial fibrillation or other arrhythmias.
• Severe visual impairment or persistent retinal changes.

• When prescribing Ivabradine, clinicians should observe several precautionary measures to ensure patient safety.
• Heart rate monitoring: verify resting heart rate ≥60 bpm before initiation.
• Sick sinus syndrome: avoid use in patients with this condition.
• Severe hepatic impairment: use with caution or avoid.
• Concomitant bradycardic agents: assess risk when combined with beta‑blockers or digoxin.
• Pregnancy and lactation: safety not established; weigh benefits against potential risks.
• Store at room temperature: keep in original packaging, protect from moisture and light.

Ivabradine interacts with several medicines; some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine plasma levels and risk of bradycardia.
• Other heart‑rate lowering drugs (beta‑blockers, digoxin, diltiazem): additive bradycardic effect.
• Concomitant use with drugs that cause QT prolongation: may increase risk of arrhythmia.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may modestly raise ivabradine concentrations.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• Antihypertensive agents: monitor blood pressure for additive effects.